Clinical Trials Using Cytokine-Induced Killer Cells

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cytokine-Induced Killer Cells. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Cytokine-Induced Killer Cells after Donor Stem Cell Transplant in Treating Patients with Refractory or Relapsed Acute Myeloid Leukemia

    This phase II trial studies how well cytokine-induced killer cells after donor stem cell transplant work in treating patients with acute myeloid leukemia that has come back or has not responded to treatment. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cytokine-induced killer cells after the transplant may stop this from happening.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Cytokine-Induced Memory-Like NK Cells in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This phase I / II trial studies the side effects and best dose of activated natural killer (NK) cells and to see how well it works in treating patients with acute myeloid leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor natural killer cell infusion may help stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's natural killer cells. Modified natural killer cells may help the body build an immune response to kill cancer cells. Aldesleukin (interleukin-2) may stimulate the white blood cells (including natural killer cells) to kill cancer cells.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri